PPARs and the complex journey to obesity
暂无分享,去创建一个
[1] M. Reitman,et al. Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. , 2003, Diabetes.
[2] Matthias Blüher,et al. Extended Longevity in Mice Lacking the Insulin Receptor in Adipose Tissue , 2003, Science.
[3] P. Puigserver,et al. A Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis , 1998, Cell.
[4] D. Smith,et al. A role for glucagon-like peptide-1 in the central regulation of feeding , 1996, Nature.
[5] J. G. Alvarez,et al. Activators of the nuclear receptor PPARγ enhance colon polyp formation , 1998, Nature Medicine.
[6] A. Garg,et al. A Novel Heterozygous Mutation in Peroxisome Proliferator-Activated Receptor-γ Gene in a Patient with Familial Partial Lipodystrophy , 2002 .
[7] Rajnish A. Gupta,et al. Activation of nuclear hormone receptor peroxisome proliferator–activated receptor-δ accelerates intestinal adenoma growth , 2004, Nature Medicine.
[8] L. Tartaglia,et al. Cloning and Characterization of an Uncoupling Protein Homolog: A Potential Molecular Mediator of Human Thermogenesis , 1997, Diabetes.
[9] B. Spiegelman,et al. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.
[10] M. Maffei,et al. Positional cloning of the mouse obese gene and its human homologue , 1994, Nature.
[11] T. Yagi,et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1 , 1994, Nature.
[12] C. Kahn,et al. Tissue-Specific Knockout of the Insulin Receptor in Pancreatic β Cells Creates an Insulin Secretory Defect Similar to that in Type 2 Diabetes , 1999, Cell.
[13] Christine Dreyer,et al. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors , 1992, Cell.
[14] R. Hegele,et al. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. , 2002, Diabetes.
[15] S. Kliewer,et al. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[16] C. Kahn,et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. , 1998, Molecular cell.
[17] A. Wolffe,et al. Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. , 1999, Journal of molecular endocrinology.
[18] B. Spiegelman,et al. Cross-Regulation of C/EBPα and PPARγ Controls the Transcriptional Pathway of Adipogenesis and Insulin Sensitivity , 1999 .
[19] L. Rossetti,et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. , 2001, The Journal of clinical investigation.
[20] L. Rossetti,et al. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. , 2003, The Journal of clinical investigation.
[21] Jourdan J. Pouliot,et al. development and , 2019 .
[22] J. Lehmann,et al. Orphan nuclear receptors: shifting endocrinology into reverse. , 1999, Science.
[23] J. Levine,et al. Role of nonexercise activity thermogenesis in resistance to fat gain in humans. , 1999, Science.
[24] P. Puigserver,et al. Transcriptional regulation of adipogenesis. , 2000, Genes & development.
[25] P. Scifo,et al. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. , 1999, Diabetes.
[26] G. Shulman,et al. On Diabetes: Insulin Resistance Cellular Mechanisms of Insulin Resistance , 2022 .
[27] G. Shulman,et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. , 2001, Genes & development.
[28] Peter Olson,et al. Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0288 Minireview: Lipid Metabolism, Metabolic Diseases, and , 2022 .
[29] M. Bucan,et al. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. , 2001, Molecular cell.
[30] M. Reitman,et al. Liver Peroxisome Proliferator-activated Receptor γ Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass* , 2003, Journal of Biological Chemistry.
[31] J. Ward,et al. Growth, Adipose, Brain, and Skin Alterations Resulting from Targeted Disruption of the Mouse Peroxisome Proliferator-Activated Receptor β(δ) , 2000, Molecular and Cellular Biology.
[32] C. Kahn,et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein , 1991, Nature.
[33] Satoshi Tanaka,et al. PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin Resistance , 1999 .
[34] StevenHaffner,et al. Epidemic Obesity and the Metabolic Syndrome , 2003 .
[35] B. Miroux,et al. Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production , 2000, Nature Genetics.
[36] Douglas L. Rothman,et al. Mitochondrial Dysfunction in the Elderly: Possible Role in Insulin Resistance , 2003, Science.
[37] G. Muscat,et al. The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. , 2003, Molecular endocrinology.
[38] D L Rothman,et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. , 1999, The Journal of clinical investigation.
[39] B. Spiegelman,et al. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. , 1997, The Journal of clinical investigation.
[40] B. Spiegelman,et al. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. , 2003, The Journal of clinical investigation.
[41] G. Shulman,et al. Mechanism by Which Fatty Acids Inhibit Insulin Activation of Insulin Receptor Substrate-1 (IRS-1)-associated Phosphatidylinositol 3-Kinase Activity in Muscle* , 2002, The Journal of Biological Chemistry.
[42] G. Shulman,et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[43] C. Kahn,et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. , 2000, Molecular cell.
[44] S. Uchida,et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature Medicine.
[45] O. Boss,et al. Uncoupling protein‐3: a new member of the mitochondrial carrier family with tissue‐specific expression , 1997, FEBS letters.
[46] Samuel Singer,et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ , 1998, Nature Medicine.
[47] J. Lehmann,et al. An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.
[48] K. Kaestner,et al. Genetic Modulation of PPARγ Phosphorylation Regulates Insulin Sensitivity , 2003 .
[49] A. Pfeiffer,et al. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. , 1998, The New England journal of medicine.
[50] Jimmy D Bell,et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. , 2003, Diabetes.
[51] Y. Terauchi,et al. The Mechanisms by Which Both Heterozygous Peroxisome Proliferator-activated Receptor γ (PPARγ) Deficiency and PPARγ Agonist Improve Insulin Resistance* , 2001, The Journal of Biological Chemistry.
[52] Jiandie D. Lin,et al. Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres , 2002, Nature.
[53] V. Mootha,et al. Mechanisms Controlling Mitochondrial Biogenesis and Respiration through the Thermogenic Coactivator PGC-1 , 1999, Cell.
[54] K. Chien,et al. PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development , 1999 .
[55] R. Evans,et al. Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[56] Weimin He,et al. Muscle-specific Pparg deletion causes insulin resistance , 2003, Nature Medicine.
[57] M. Lazar,et al. The hormone resistin links obesity to diabetes , 2001, Nature.
[58] M. Lazar,et al. A futile metabolic cycle activated in adipocytes by antidiabetic agents , 2002, Nature Medicine.
[59] Christophe Fleury,et al. Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia , 1997, Nature Genetics.
[60] Bruno Derudas,et al. Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity* , 2000, The Journal of Biological Chemistry.
[61] J. Ju,et al. Skeletal muscle respiratory uncoupling prevents diet-induced obesity and insulin resistance in mice , 2000, Nature Medicine.
[62] P. Scherer,et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action , 2001, Nature Medicine.
[63] J. H. Johnson,et al. Thiazolidinediones and insulin resistance: peroxisome proliferatoractivated receptor gamma activation stimulates expression of the CAP gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[64] Martin D. Brand,et al. Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean , 2000, Nature.
[65] Bruce A. Johnson,et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. , 2003, Molecular endocrinology.
[66] K. Jarnagin,et al. The human insulin receptor cDNA: The structural basis for hormone-activated transmembrane signalling , 1985, Cell.
[67] B. Lowell,et al. UCP3: an uncoupling protein homologue expressed preferentially and abundantly in skeletal muscle and brown adipose tissue. , 1997, Biochemical and biophysical research communications.
[68] R. Evans,et al. Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity , 2003, Cell.
[69] B. Spiegelman,et al. PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro , 1999 .
[70] Rene Devos,et al. Identification and expression cloning of a leptin receptor, OB-R , 1995, Cell.
[71] Y. Terauchi,et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.
[72] Philippe Froguel,et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects , 2003, Nature.
[73] S. Woods,et al. Monitoring of stored and available fuel by the CNS: implications for obesity , 2003, Nature Reviews Neuroscience.
[74] Rachel L. Batterham,et al. Gut hormone PYY3-36 physiologically inhibits food intake , 2002, Nature.
[75] M. Benito,et al. Brown adipose tissue-specific insulin receptor knockout shows diabetic phenotype without insulin resistance. , 2001, The Journal of clinical investigation.
[76] A. Stunkard,et al. A twin study of human obesity. , 1986, JAMA.
[77] M. Nakazato,et al. A role for ghrelin in the central regulation of feeding , 2001, Nature.
[78] W. Kraus,et al. Fatty Acid Homeostasis and Induction of Lipid Regulatory Genes in Skeletal Muscles of Peroxisome Proliferator-activated Receptor (PPAR) α Knock-out Mice , 2002, The Journal of Biological Chemistry.
[79] W. Wahli,et al. Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting , 1999 .
[80] K. Umesono,et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[81] K. Umesono,et al. The nuclear receptor superfamily: The second decade , 1995, Cell.
[82] G. Shulman,et al. Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. , 2003, Diabetes.
[83] C. Burant,et al. Troglitazone action is independent of adipose tissue. , 1997, The Journal of clinical investigation.
[84] V. Mootha,et al. Energy Metabolism in Uncoupling Protein 3 Gene Knockout Mice* , 2000, The Journal of Biological Chemistry.
[85] William Arbuthnot Sir Lane,et al. Role of IRS-2 in insulin and cytokine signalling , 1995, Nature.
[86] G. Muscat,et al. The Peroxisome Proliferator-Activated Receptor / Agonist , GW 501516 , Regulates the Expression of Genes Involved in Lipid Catabolism and Energy Uncoupling in Skeletal Muscle Cells , 2003 .
[87] R. Evans,et al. Nuclear receptors and lipid physiology: opening the X-files. , 2001, Science.
[88] T. Hashimoto,et al. PEROXISOMAL β-OXIDATION AND PEROXISOME PROLIFERATOR–ACTIVATED RECEPTOR α: An Adaptive Metabolic System , 2001 .
[89] B. Spiegelman,et al. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. , 2002, Genes & development.
[90] B. Spiegelman,et al. Expression of the mitochondrial uncoupling protein gene from the aP2 gene promoter prevents genetic obesity. , 1995, The Journal of clinical investigation.
[91] R. Evans,et al. Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency , 2000 .
[92] B. Brewer,et al. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. , 2003, The Journal of clinical investigation.
[93] J. Auwerx,et al. Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPARγ hypomorphic mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[94] L. Chao,et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. , 2000, The Journal of clinical investigation.
[95] Bruce M. Spiegelman,et al. Towards a molecular understanding of adaptive thermogenesis , 2000, Nature.
[96] Y. Kido,et al. Impaired glucose tolerance in mice with a targeted impairment of insulin action in muscle and adipose tissue , 1998, Nature Genetics.
[97] J. Auwerx,et al. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice , 1998, Nature Medicine.
[98] Hitoshi Yamashita,et al. Mice lacking mitochondrial uncoupling protein are cold-sensitive but not obese , 1997, nature.
[99] William A. Boisvert,et al. Transcriptional Repression of Atherogenic Inflammation: Modulation by PPARδ , 2003, Science.
[100] Weimin He,et al. Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[101] G. Shulman,et al. Disruption of IRS-2 causes type 2 diabetes in mice , 1998, Nature.
[102] P. H. Seeburg,et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes , 1985, Nature.
[103] B. Lowell,et al. βAR Signaling Required for Diet-Induced Thermogenesis and Obesity Resistance , 2002, Science.
[104] Mark D. Johnson,et al. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene , 1996, Nature Genetics.
[105] S. Woods,et al. Peripheral signals in the control of satiety and hunger , 2003, Current opinion in clinical nutrition and metabolic care.
[106] Johan Auwerx,et al. Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[107] W. Wahli,et al. Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.
[108] M. Reitman,et al. WY14,643, a Peroxisome Proliferator-activated Receptor α (PPARα) Agonist, Improves Hepatic and Muscle Steatosis and Reverses Insulin Resistance in Lipoatrophic A-ZIP/F-1 Mice* , 2002, The Journal of Biological Chemistry.
[109] I. Issemann,et al. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.
[110] C. Glass,et al. Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[111] R. Evans,et al. The RXR heterodimers and orphan receptors , 1995, Cell.
[112] M. Maffei,et al. Positional cloning of the mouse obese gene and its human homologue , 1995, Nature.